A phase 1/2 trial of TTX-MC138 in advanced solid tumours, run by TransCode Therapeutics, active and no longer recruiting.
Study of TTX-MC138 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06260774 by TransCode Therapeutics, with 16 participants enrolled, started 2024-09-05 and due to reach its primary completion in 2025-09-30. Interventions recorded: TTX-MC138.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.